Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
TRIPLE-SWITCH
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- NCT06592924 ↗
- Recruiting
- Canadian Cancer Trials Group
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 27 | |
| YouTube | 19 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Prostate Cancer (Adenocarcinoma)
- Interventions
- Abiraterone; Enzalutamide; Apalutamide; Darolutamide (BAY 1841788); Docetaxel; ADT
- Arms
- Standard ADT + ARPI · Active comparator
- Docetaxel + Standard ADT + ARPI · Experimental
- Enrollment
- 830 (estimated)
- Primary outcomes
- Overall Survival
- Sponsor
- Canadian Cancer Trials Group with ECOG-ACRIN Cancer Research Group, NRG Oncology, Alliance for Clinical Trials in Oncology, SWOG Cancer Research Network
- Start
- May 28, 2025
- Primary completion
- Mar 14, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT06592924 · updated Jul 14, 2026